Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma.

MLA

Derenzini, Enrico, et al. “Therapeutic Implications of Intratumor Heterogeneity for TP53 Mutational Status in Burkitt Lymphoma.” Experimental Hematology & Oncology, vol. 4, Aug. 2015, p. 24. EBSCOhost, https://doi.org/10.1186/s40164-015-0019-9.

APA

Derenzini, E., Iacobucci, I., Agostinelli, C., Imbrogno, E., Storlazzi, C. T., L Abbate, A., Casadei, B., Ferrari, A., Di Rora, A. G. L., Martinelli, G., Pileri, S., & Zinzani, P. L. (2015). Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma. Experimental Hematology & Oncology, 4, 24. https://doi.org/10.1186/s40164-015-0019-9

Chicago

Derenzini, Enrico, Ilaria Iacobucci, Claudio Agostinelli, Enrica Imbrogno, Clelia Tiziana Storlazzi, Alberto L Abbate, Beatrice Casadei, et al. 2015. “Therapeutic Implications of Intratumor Heterogeneity for TP53 Mutational Status in Burkitt Lymphoma.” Experimental Hematology & Oncology 4 (August): 24. doi:10.1186/s40164-015-0019-9.